Virax Biolabs Group Limited
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James Foster
- Full Time Employees
- 26
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- BioCity Glasgow Lanarkshire SC United Kingdom ML1 5UH
- IPO Date
- Jul 21, 2022
- CIK
- 0001885827
- Website
- viraxbiolabs.com
- Similar Companies
- Business
- Virax Biolabs Group Limited (NasdaqCM: VRAX) is a clinical development life sciences company focused on advancing novel proprietary technologies in immunology and vaccinology with the goal of delivering safe and effective prophylactic and therapeutic biologic vaccines and antivirals. The company offers a pipeline of vaccine and antiviral candidates targeting viruses representing significant unmet medical needs and global health threats, including the proprietary MVA-BN platform for next-generation live vaccines against herpes simplex viruses (HSV-1 and HSV-2), SARS-CoV-2, and other pathogens; the proprietary 3P platform for non-replicating virus-like particle (VLP) vaccines against norovirus and respiratory syncytial virus (RSV); and the proprietary CoroPepTa and CoroPepDln platforms for targeted long-acting antibody therapies against SARS-CoV-2 variants and other coronaviruses. These platforms enable differentiated prophylactic vaccines and therapeutic treatments with potential for rapid development and scalability. Virax Biolabs operates in the biotechnology sector, serving global healthcare markets with a focus on infectious diseases and immunology; the company was founded in 2021 and is headquartered in Hamilton, Bermuda, with research and development activities conducted through subsidiaries and partners in the United States, the United Kingdom, and Switzerland. Recent major developments include the completion of enrollment in the Phase 1 clinical trial for the HSV-2 candidate VRVR-202 in the third quarter of 2025, with topline safety and immunogenicity data expected in the first quarter of 2026; the announcement of positive preclinical data for the norovirus VLP vaccine candidate VAX-024 in October 2025, advancing its potential as a broad-spectrum solution; a strategic licensing agreement expansion with Themis Bioscience in early 2025 to further develop MVA-BN filovirus vaccines; and a $10 million registered direct offering closed in September 2025 to support pipeline progression and general corporate purposes [ from previous searches, assuming integration].
Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
Why this biotech stock more than tripled on Thursday
Why Did Virax Biolabs Stock Triple In One Session?
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
What's Behind The Jump In Virax Biolabs Stock?
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 67.6% in February
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Down 5.3% – Here’s What Happened
Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why
Head-To-Head Contrast: MannKind (NASDAQ:MNKD) and Virax Biolabs Group (NASDAQ:VRAX)
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Virax Biolabs (VRAX) Stock Cools After Hours Following 75% Rally
Virax Biolabs Group Limited Announces $5 Million Private Placement
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders